Cargando…
Correction to: Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System
Autores principales: | McDaniel, Lauren F., White, Melissa N., Obi, Engels N., Kohinke, Rose M., Lockhart, Ellen Rachel S., Chipriano, Damian J., Chen, Yiyun, Everson, Nathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868219/ https://www.ncbi.nlm.nih.gov/pubmed/36459384 http://dx.doi.org/10.1007/s40121-022-00721-w |
Ejemplares similares
-
Clinical and Economic Outcomes After Implementation of a Fidaxomicin Treatment Optimization and Access Pathway at a US Hospital System
por: McDaniel, Lauren F., et al.
Publicado: (2022) -
762. Real-World Utilization of C. difficile Drug Treatments and Associated Clinical Outcomes in a US Hospital System
por: McDaniel, Lauren, et al.
Publicado: (2021) -
2437. First-line Fidaxomicin Use in High-risk Inpatients Reduces Recurrence Rates
por: Kohinke, Rose, et al.
Publicado: (2019) -
693. Clinical and Economic Outcomes Associated with Fidaxomicin in Comparison to Vancomycin, Metronidazole, and FMT: a Systematic Literature Review
por: Li, Qinghua, et al.
Publicado: (2023) -
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
por: Jiang, Yiling, et al.
Publicado: (2022)